- Home
- MDXG vs NMRA Comparison
MDXG vs NMRA Comparison
Compare MDXG & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDXG | NMRA |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.2M | 554.0M |
| IPO Year | 2007 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MDXG | NMRA |
|---|---|---|
| Price | $3.68 | $1.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $9.00 | $7.50 |
| AVG Volume (30 Days) | 1.1M | ★ 3.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,630,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.99 | N/A |
| 52 Week Low | $3.03 | $0.72 |
| 52 Week High | $7.99 | $3.65 |
Technical Indicators
Market Signals| Indicator | MDXG | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 43.66 |
| Support Level | $3.47 | N/A |
| Resistance Level | $3.84 | $2.08 |
| Average True Range (ATR) | 0.13 | 0.17 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 52.50 | 62.73 |
Price Performance
Historical ComparisonAbout MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.